[New oral anticoagulants - influence on coagulation tests].

Simeon, L; Nagler, Michael; Wuillemin, Walter Alfred (2014). [New oral anticoagulants - influence on coagulation tests]. Deutsche medizinische Wochenschrift, 139(3), pp. 94-99. Thieme 10.1055/s-0033-1359920

Text 2014 Dtsch Med Wochenschr_Simeon.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (289kB) | Request a copy

The new oral anticoagulants (NOACs) represent alternative antithrombotic agents for prophylaxis and therapy of thromboembolic diseases. They act either by inhibition of the clotting factor Xa or IIa (thrombin). As a consequence, they influence several coagulation assays (for example prothrombin time, activated partial thromboplastin time). Because of the short half-life of these new agents, these changes show great variations in the course of 24 hours. Furthermore, there are significant differences of laboratory results depending on the used reagents. We explain the influence of apixaban, rivaroxaban (factor Xa inhibitors) and dabigatran (thrombin inhibitor) on the most commonly used coagulation assays. Besides we show that this influence depends on the way of action of the drug as well as on the principle of the coagulation assay. Being aware of this relationships helps to interpret the results of coagulation assays under influence of NOACs correctly.

Interest & Impact

Downloads

4 since deposited on 30 Sep 2014
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item